The mechanisms of alloxan- and streptozotocin-induced diabetes
暂无分享,去创建一个
[1] E. Wilander,et al. Distribution of labelled streptozotocin in mice: uptake and retention in pancreatic islets. , 1976, The Journal of endocrinology.
[2] W. Malaisse,et al. Long term in vitro effects of streptozotocin, interleukin-1, and high glucose concentration on the activity of mitochondrial dehydrogenases and the secretion of insulin in pancreatic islets. , 1992, Endocrinology.
[3] S. Lenzen,et al. Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme. , 1988, Molecular pharmacology.
[4] J. Patterson,et al. The Mechanism of Cysteine and Glutathione Protection Against Alloxan Diabetes. , 1948, Science.
[5] A. P. Autor. Pathology of oxygen , 1982 .
[6] S. Marklund,et al. Influence of trace metals on alloxan cytotoxicity in pancreatic islets , 1979, FEBS letters.
[7] V. Devita,et al. Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998) , 1974, Cancer.
[8] O. Korsgren,et al. Functional characteristics of cultured mouse pancreatic islets following exposure to different streptozotocin concentrations , 1988, Molecular and Cellular Endocrinology.
[9] N. McLetchie,et al. EXPERIMENTAL ALLOXAN DIABETES IN THE RAT , 1943 .
[10] J. Logothetopoulos,et al. Proinsulin biosynthesis by pancreatic islets of the rat and the study of alloxan cytotoxicity in vitro. , 1976, Biochimica et biophysica acta.
[11] S. Lenzen,et al. Relation between triketone structure, generation of reactive oxygen species, and selective toxicity of the diabetogenic agent alloxan. , 2008, Antioxidants & redox signaling.
[12] H. Kolb,et al. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin , 1999, Nature Medicine.
[13] S. Lenzen,et al. Alloxan: history and mechanism of action , 1988, Diabetologia.
[14] C. D. Barry,et al. Molecular requirements for recognition at glucoreceptor for insulin release. , 1979, Molecular pharmacology.
[15] H. Okamoto,et al. Protection by superoxide dismutase, catalase, and poly(ADP-ribose) synthetase inhibitors against alloxan- and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis. , 1982, The Journal of biological chemistry.
[16] B. Lin,et al. Interaction of Alloxan and Anomers of D-Glucose on Glucose-induced Insulin Secretion and Biosynthesis in Vitro , 1976, Diabetes.
[17] R. Munday,et al. Importance of the GLUT2 glucose transporter for pancreatic beta cell toxicity of alloxan , 2002, Diabetologia.
[18] M. Mcdaniel,et al. Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. , 1993, Biochemical and biophysical research communications.
[19] W. Malaisse,et al. Defective catabolism of D-glucose and L-glutamine in mouse pancreatic islets maintained in culture after streptozotocin exposure. , 1988, Endocrinology.
[20] T Szkudelski,et al. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. , 2001, Physiological research.
[21] M. Glitzer,et al. Light and Electron Microscopy of Lesions in Rats Rendered Diabetic with Streptozotocin , 1967, Diabetes.
[22] I. Swenne,et al. Streptozotocin, but not alloxan, induces DNA repair synthesis in mouse pancreatic islets in vitro , 1983, Diabetologia.
[23] H. Hara,et al. Parallel Inhibition of Islet Glucokinase and Glucose-Stimulated Insulin Secretion by Either Alloxan or Ninhydrin , 1986 .
[24] J. Okuda,et al. Inhibition of rat liver glucokinase by alloxan and ninhydrin. , 1986, Chemical & pharmaceutical bulletin.
[25] H. Ebelt,et al. ‘Classical’ and ‘new’ diabetogens—comparison of their effects on isolated rat pancreatic islets in vitro , 2000, Cellular and Molecular Life Sciences CMLS.
[26] S. Lenzen,et al. Mechanism underlying resistance of human pancreatic beta cells against toxicity of streptozotocin and alloxan , 2003, Diabetologia.
[27] M. Welsh,et al. Exposure of pancreatic islets to different alkylating agents decreases mitochondrial DNA content but only streptozotocin induces long-lasting functional impairment of B-cells. , 1991, Biochemical pharmacology.
[28] Konstantin Bloch,et al. Streptozotocin and Alloxan-based Selection Improves Toxin Resistance of Insulin-Producing RINm Cells , 2000, International journal of experimental diabetes research.
[29] S. Lenzen,et al. Inhibition of aconitase by alloxan and the differential modes of protection of glucose, 3-O-methylglucose, and mannoheptulose , 1992, Naunyn-Schmiedeberg's Archives of Pharmacology.
[30] W. Malaisse,et al. Pancreatic uptake of [2-(14)C]alloxan. , 2001, International journal of molecular medicine.
[31] J. E. Kudlow,et al. The role of O-linked protein glycosylation in β-cell dysfunction (review) , 2002 .
[32] S. Snyder,et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Patterson,et al. Alloxan and dialuric acid; their stabilities and ultraviolet absorption spectra. , 1949, The Journal of biological chemistry.
[34] L. Oberley. Free radicals and diabetes. , 1988, Free radical biology & medicine.
[35] M. Goldner,et al. Acute Nature of Alloxan Damage.* , 1945 .
[36] R. Munday,et al. Comparative toxicity of alloxan, N-alkylalloxans and ninhydrin to isolated pancreatic islets in vitro. , 1997, The Journal of endocrinology.
[37] G. Cohen,et al. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.
[38] R. Heikkila,et al. The prevention of alloxan-induced diabetes in mice by the iron-chelator detapac: Suggestion of a role for iron in the cytotoxic process , 1982, Experientia.
[39] H. Ebelt,et al. Scavenging effect of melatonin on hydroxyl radicals generated by alloxan , 2000, Journal of pineal research.
[40] C. Newgard,et al. STZ Transport and Cytotoxicity: Specific Enhancement in GLUT2-Expressing Cells , 1994, Diabetes.
[41] S. Marklund,et al. Superoxide dismutase, catalase and scavengers of hydroxyl radical protect against the toxic action of alloxan on pancreatic islet cells in vitro. , 1979, The Biochemical journal.
[42] Zhiyong Wang,et al. GLUT2 in Pancreatic Islets: Crucial Target Molecule in Diabetes Induced With Multiple Low Doses of Streptozotocin in Mice , 1998, Diabetes.
[43] N. J. Patton,et al. Mechanisms of Nitrosourea-Induced β-Cell Damage: Alterations in DNA , 1986, Diabetes.
[44] P. Schein,et al. The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. , 1967, Cancer research.
[45] C. D. Barry,et al. Alloxan Stimulation and Inhibition of Insulin Release from Isolated Rat Islets of Langerhans , 1978, Diabetes.
[46] P. Lacy,et al. Alloxan uptake by isolated rat islets of Langerhans. , 1978, Endocrinology.
[47] L. Borg. Effects of alloxan on the islets of Langerhans: inhibition of leucine metabolism and insulin secretion. , 1981, Biochimica et biophysica acta.
[48] A. Pegg,et al. Alkylation of DNA in rat tissues following administration of streptozotocin. , 1981, Cancer research.
[49] S. Lenzen,et al. Importance of cysteine residues for the stability and catalytic activity of human pancreatic beta cell glucokinase. , 2000, Archives of biochemistry and biophysics.
[50] R. Munday,et al. Glutathione-mediated redox cycling of alloxan. Mechanisms of superoxide dismutase inhibition and of metal-catalyzed OH. formation. , 1989, Biochemical pharmacology.
[51] L. Hammarström,et al. On the accumulation of alloxan in the pancreatic β-cells , 1967, Diabetologia.
[52] R. Weiss. Streptozocin: a review of its pharmacology, efficacy, and toxicity. , 1982, Cancer treatment reports.
[53] N. Rakieten,et al. Studies on the diabetogenic action of streptozotocin (NSC-37917). , 1963, Cancer chemotherapy reports.
[54] D. Pipeleers,et al. Selective uptake of alloxan by pancreatic B-cells. , 1982, The Biochemical journal.
[55] H. Sheehan,et al. NECROSIS OF ISLETS OF LANGERHANS PRODUCED EXPERIMENTALLY , 1943 .
[56] J. Cunningham,et al. Comparison of inhibition of glucose-stimulated insulin secretion in rat islets of Langerhans by streptozotocin and methyl and ethyl nitrosoureas and methanesulphonates. Lack of correlation with nitric oxide-releasing or O6-alkylating ability. , 1995, Biochemical pharmacology.
[57] N. J. Patton,et al. Mechanisms of nitrosourea-induced beta-cell damage. Alterations in DNA. , 1986, Diabetes.
[58] E. Wertheimer,et al. Alloxan studies; the action of alloxan homologues and related compounds. , 1947, The Journal of biological chemistry.
[59] R. Munday,et al. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin , 2000, Diabetologia.
[60] I. Gelfand,et al. Lessons from Animal Diabetes VI , 1996, Rev.Ser.Advs.Research Diab.Animals (Birkhäuser).
[61] R. Munday,et al. Effect of superoxide dismutase, catalase, chelating agents, and free radical scavengers on the toxicity of alloxan to isolated pancreatic islets in vitro. , 1999, Free radical biology & medicine.
[62] S. J. Cooperstein,et al. 15 – Action of Toxic Drugs on Islet Cells , 1981 .
[63] G. Bhattacharya,et al. Reversal of the diabetogenic action of alloxan by sulfhydryl compounds. , 1952, Science.
[64] R. Munday,et al. Thiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N-methyl derivatives and a comparison with ninhydrin. , 1991, Biochemical pharmacology.
[65] M. Goldner,et al. ALLOXAN DIABETES IN THE DOG1 , 1943 .
[66] R. Munday,et al. The relationship between the physicochemical properties and the biological effects of alloxan and several N-alkyl substituted alloxan derivatives. , 1993, The Journal of endocrinology.
[67] J. Liebig,et al. Untersuchungen über die Natur der Harnsäure , 1838 .
[68] C. Rerup. Drugs producing diabetes through damage of the insulin secreting cells. , 1970, Pharmacological reviews.
[69] R. Munday,et al. Alloxan derivatives as a tool for the elucidation of the mechanism of the diabetogenic action of alloxan , 1996 .
[70] R. Munday. Dialuric acid autoxidation. Effects of transition metals on the reaction rate and on the generation of "active oxygen" species. , 1988, Biochemical pharmacology.
[71] C. Hellerström,et al. Acute Effects of Alloxan on the Metabolism and Insulin Secretion of the Pancreatic B-Cell , 1973, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[72] J. E. Kudlow,et al. The role of O-linked protein glycosylation in beta-cell dysfunction. , 2002, International journal of molecular medicine.
[73] P. Schein,et al. Streptozotocin: depression of mouse liver pyridine nucleotides. , 1968, Cancer research.
[74] S. Kawanishi,et al. Site-specific DNA methylation and apoptosis: induction by diabetogenic streptozotocin. , 1999, Biochemical pharmacology.
[75] G. Cohen,et al. Alloxan-induced diabetes-evidence for hydroxyl radical as a cytotoxic intermediate. , 1976, Biochemical pharmacology.
[76] N. McLetchie. Alloxan diabetes: The sorcerer and his apprentice , 1982, Diabetologia.
[77] N. J. Patton,et al. Mechanisms of Nitrosourea-Induced β-Cell Damage: Activation of Poly (ADP-Ribose) Synthetase and Cellular Distribution , 1988, Diabetes.
[78] S. Lenzen,et al. INHIBITION OF GLUCOKINASE AND HEXOKINASE FROM PANCREATIC B-CELLS AND LIVER BY ALLOXAN, ALLOXANTIN, DIALURIC ACID, AND t-BUTYLHYDROPEROXIDE , 1991 .
[79] R. Heikkila,et al. Protection against alloxan-induced diabetes by various urea derivatives: relationship between protective effects and reactivity with the hydroxyl radical. , 1979, The Journal of pharmacology and experimental therapeutics.
[80] S. Lenzen,et al. Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibition , 1988, British journal of pharmacology.
[81] S. Lenzen,et al. Relation Between Antioxidant Enzyme Gene Expression and Antioxidative Defense Status of Insulin-Producing Cells , 1997, Diabetes.
[82] N. Rakieten. Studies on the diabetogenic action of streptozotocin , 1963 .
[83] F. Bedoya,et al. N-Monomethyl-arginine and nicotinamide prevent streptozotocin-induced double strand DNA break formation in pancreatic rat islets , 1996, Experientia.
[84] A. Preston. Modification of streptozotocin-induced diabetes by protective agents , 1985 .
[85] W. Cowden,et al. Auto-oxidation of dialuric acid, divicine and isouramil. Superoxide dependent and independent mechanisms. , 1989, Biochemical pharmacology.
[86] L. Hammarström,et al. On the accumulation of alloxan in the pancreatic beta-cells. , 1967, Diabetologia.
[87] H. Okamoto,et al. Streptozotocin and alloxan induce DNA strand breaks and poly(ADP–ribose) synthetase in pancreatic islets , 1981, Nature.
[88] S. Snyder,et al. Poly (ADP-ribose) polymerase, nitric oxide and cell death. , 1999, Trends in pharmacological sciences.
[89] S. Lenzen,et al. Relative importance of cellular uptake and reactive oxygen species for the toxicity of alloxan and dialuric acid to insulin-producing cells. , 2006, Free radical biology & medicine.
[90] T. Ochiya,et al. Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[91] H. Najafi,et al. Identification of Glucokinase as an Alloxan-Sensitive Glucose Sensor of the Pancreatic β-Cell , 1986, Diabetes.
[92] S. Lenzen,et al. Glucokinase in pancreatic B-cells and its inhibition by alloxan. , 1987, Acta endocrinologica.
[93] S. Lenzen,et al. Signal recognition by pancreatic B-cells. , 1988, Biochemical pharmacology.
[94] D. Hearse,et al. Autoradiographic study of the distribution and cellular uptake of (14C)-streptozotocin in the rat , 1976, Diabetologia.
[95] R. Lorentzon,et al. Uptake of labeled alloxan in mouse organs and mitochondria in vivo and in vitro. , 1983, Endocrinology.
[96] S. Ledoux,et al. Effects of streptozotocin on a clonal isolate of rat insulinoma cells. , 1984, Biochimica et biophysica acta.